Buy Visomitin eye drops 5 ml

Visomitin eye drops 5 ml

Condition: New product

900 Items

30,19 $

More info

Active ingredients

Plastoquinonyldecyltriphenylphosphonium bromide

Release form

Drops

Composition

Active ingredient: Plastoquinonyldecyltriphenylphosphonium bromide (PDTF) 0, 155 mcg. Auxiliary substances: Benzalkonium chloride 0, 1 mg, hypromellose 2 mg, sodium chloride 9 mg, sodium dihydrophosphate dihydrate 0, 81 mg, sodium, iodine, 9 mg, sodium hydrophosphate, 81 mg, sodium hydrogen, 9 mg, sodium hydride, calcium sulfate, 9 mg, sodium dihydrophosphate dihydrate 0, 81 mg; mcg

Pharmacological effect

Plastoquinonyldecyltriphenylphosphomy bromide (PDTP) is a derivative of plastoquinone, which is linked through a linker chain (CU) to the triphenylphosphine residue. PDTP in low (nanomolar) concentrations exhibits high antioxidant activity. It also has a stimulating effect on the process of tear production, epithelization, contributes to the stability of the tear film.

Pharmacokinetics

No human pharmacokinetic studies have been performed. In preclinical studies in animals, the distribution of PDTP in organs and tissues occurred within 48 hours after IV and intragastric administration. It was found that PDTP is present in the highest concentrations in the tissues of the kidney, liver and heart within 1 hour after administration. PDTP relatively quickly undergoes enzymatic cleavage and covalent binding to proteins.

Indications

The syndrome of "dry eye". The initial stage of age-related cataract.

Contraindications

Hypersensitivity to the components of the drug, age up to 18 years.

Use during pregnancy and lactation

Adequate controlled studies in pregnant and lactating women have not been conducted. It is not recommended to prescribe the drug during pregnancy. If you need an appointment during lactation for the period of treatment, breastfeeding should be stopped.

Dosage and administration

Dry eye syndrome: 1-2 drops of the drug in the conjunctival sac 3 times a day. The duration of the course of treatment is determined by the doctor depending on the severity of the disease. The initial stage of age-related cataract: 1-2 drops of the drug in the conjunctival sac 3 times a day. Duration of treatment is 6 months. During drug therapy, an ophthalmologist should be monitored to assess the degree of disease progression and the need to continue conservative therapy.

Side effects

Allergic reactions. From the senses: perhaps a short-term burning sensation and cramps in the eyes after instillation.

Overdose

Data on overdose with local use are not available.

Interaction with other drugs

If necessary, you can apply simultaneously with other eye drops. In this case, the interval between instillations must be at least 5 minutes.

special instructions

Influence on the ability to drive vehicles and control mechanisms

Reviews